DC12 reduces hepatic steatosis, inflammation, and fibrosis ‐hallmarks of MASH progression‐ highlighting its potential as a promising option for both the prevention and treatment of MASH. This evidence concerns the gene HMCES and metabolic dysfunction-associated steatohepatitis.